(Q39166082)
Statements
Limited effectiveness and safety profile of protease inhibitor-based triple therapy against chronic hepatitis C in a real-world cohort with a high proportion of advanced liver disease (English)
Michael P Manns
Heiner Wedemeyer
Christoph Höner Zu Siederdissen
Kerstin Port
Katja Deterding
Antoaneta A Markova
Magdalena Rogalska-Taranta